Τόμος 28 (2010) – Τεύχος 3 – Άρθρο 7 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 28 (2010) – Issue 3 – Article 7 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Ε. Κοντακιώτη, Ζ. Μπούσιου, Μ. Τσιαούση, Μ. Μυρωνίδου-Τζουβελέκη

Ά Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

E. Kontakioti, Z. Boussiou, M. Tsiaousi, M. Mironidou- Tzouveleki

A’ Laboratory of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece

2. Οικονόμου Α., Καββαδίας Τ., Οικονόμου Κ., Μυρωνίδου-Τζουβελέκη Μ.: Ενδείξεις χορήγησης εκλεκτικών αναστολέων επαναπρόσληψης σεροτονίνης σε παιδιά και εφήβους, Τόμος περιλήψεων του 10ου Επιστημονικού Συνεδρίου Φοιτητών Ιατρικής Ελλάδος, Μάιος 2004, Θεσσαλονίκη, σελ. 201.

3. Lusskin S., Pundiak T., Habib S.: Perinatal Depression: Hiding in Plain Sight. Can. J. Phychiatry 8: 479 (2007)

4. Marchesi C., Bertoni S., Maggini C.: Major and minor depression in pregnancy. Obstet. Gynecol.113: 1292-1298 (2009)

5. Wisner K., Gelenberg A., Leonard H,, Zarin D,, Frank E.: Pharmacologic treatment of depression during preg-nancy. JAMA 282: 1264-1269 (1999)

6. Εθνικό συνταγολόγιο, ΕΟΦ, Αθήνα, 2007, σελ. 212-222.

7. Harvey R., Champe P.: Φαρμακολογία. 3η έκδοση, σελ. 129-136, εκδόσεις Παρισιάνου, Αθήνα, 2007

8. Wisner K., Zarin D., Holmboe E., Appelbaum P., Gelenberg A., Leonard H., Frank E.: Risk- Benefit decision making for treatment of depression during pregnancy. Am. J. Psychiatry 157: 1933-1939 (2000)

9. Hemels M., Einarson A., Koren G., Lanctôt K., Einarson T.R.: Antidepressant use during pregnancy and the rates of spontaneous abortions: A meta-analysis. Ann. Pharmacother. 39: 803-809 (2005)

10. Ramos E., Oraichi D., Rey E., Blais L., Berard A.: Prevalence and predictors of antidepressant use in a cohort pregnant women. BJOG 114:1055-1064 (2007)

11. Maschi S., Clavenna A., Campi R., Schiavetti B., Bernat M., Bonati M.: Neonatal outcome following pregnancy exposure to antidepressants:a prospective controlled cohort study. BJOG 115: 283-289 (2008)

12. Bakker M., Kölling P., van den Berg P., de Walle L.H., de Jong van den Berg T.: Increases in use of selective serotonine reuptake inhibitors in pregnancy during the last decade, a population based cohort study from the Netherlands BJCP 65: 600-604 (2007)

13. De las Cuevas C., J. Sanz E.: Safety of selective serotonin reuptake inhibitors in pregnancy. Curr. Drug Safety 1: 17-24 (2006)

14. Kinger G., Merlob P.: Selective serotonine reuptake inhibitor induced neonatal abstinence syndrome. Ish. J. Psychiatry Relat. Sci. 45: 107-113 (2008)

15. Rampono J., Simmer K., Ilett F., Hackett L.P., Doherty D.A., Elliot R., Kok C.H., Coenen A.: Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42: 95-100 (2009)

16. Malm H., Klaukka T., Neuvonen P.J.: Risks associated with selective serotonine reuptake inhibitors in pregnancy. Obstet. Gynecol. 106: 1289-1296 (2005)

17. Oberlander T., Warburton W., Misri S., Aghajanian J., Hertzman C.: Neonatal outcome after prenatal exposure to selective serotonine reuptake inhibitor antidepressans ant maternal depression using population based linked health data. Arch. Gen. Psychiatry 3: 898-906 (2006)

18. Davis R.L., Rubanowice D., McPhillips H., Raebel M.A., Andrade S.E., Smith D., et al.: Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy, Pharmacoepidemiol. Drug Safety 16: 1086-1094 (2007)

19. Wogeliuw P., Nørgaard N., Gislum M., Pedersen L., Munk E., Bo Mortensen P., Lipworth L., Toft Sørensen H.: Maternal use of selective serotonine reuptake inhibitors and risk of congenital malformations. Epidemiology 17: 701-704 (2006)

20. Berard A., Ramos E., Rey E., Blais L., St.-Andre M., Oraichi D.: First trimester exposure to paroxetine and risk of cardiac malformations in infants: The importance of dosage. Birth Defects Res. (Part B) 80: 18-27 (2007)

21. Baroz B., Einarson T., Einarson A., Boskovic R., O’Brien L., Malm H. et al.: Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin. Ther. 29: 918-926 (2007)

22. Louik C., Lin A., Werler M,, Hernández-Díaz S,, Mitchell A.: First tremester use of selective serotonine reuptake inhibitors ant the risk of birth defects. NEJM 356: 2675-2683 (2007)

23. Moses-Kolko E.L., Bogen D., Perel J., et al.: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications. JAMA 293: 2372-2383 (2005)

24. Pediatric Pharmacotherapy: Determining the degree of drug transfer (1996). Availiable on
www.healthsystem.virginia.edu/alive/pediatrics/PharmNews/199604.pdf

25. Malone K., Papagni K., Ramini S., Keltner N.: Antide-pressants, antipsychotics, benzodiazepines, and the breastfeeding dyad. Psychiatric Care 40(2): 73-85 (2004)

26. Gentile S., Rossi A., Bellantuono C.: SSRIs during breastfeeding: spotlight on milk-to-plasma ratio. Arch. Women Ment. Health 10: 39-51 (2007)

27. Rampono J., et al.: Transfer of escitalopram and its metabolite demethylescitalopram into breast milk. Br. J. Clin. Phamacol. 62: 316-322 (2οο6)

28. Berle J., Steen V., Aamo Tr.: Breastfeeding during maternal antidepressant treatment with Serotonin Reuptake Inhibitors: Infant exposure, clinical symptoms, and cytochrome P450 genotypes. J. Clin. Psychiatry 65: 1228-1234 (2004)

29. Hendrick V., Fukuchi A., Altshuler L., Widawski M., Wertheimer A., Brunhuber M.: Use of sertraline, paroxetine and fluvoxamine by nursing women. Br. J. Psychiatry 179: 163-166 (2001)

30. Stowe Z.N., Cohen L.S., Hostetter A., Ritchie J.C., Owens M.J., Nemeroff C.B.: Paroxetine in human breast milk and nursing infants. Am. J. Psychiatry 157: 185-189 (2000)

31. Epperson N., et al.: Maternal Sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am. J. Psychiatry 158: 1631-1637 (2001)

32. Wisner K., Perel J., Blumer J.: Serum sertraline and N-Desmethylsertraline levels in breast-feeding mother-infant pairs. Am. J. Psychiatry 155: 690-692 (1998)

33. Stowe Z., Owens M.J., Landry J.C., Kilts C.D., Ely T., Llewellyn A., Nemeroff C.B.: Sertraline and desmathyser-traline in human breast milk and nursing infants. Am. J. Psychiatry 154: 1255-1260 (1997)

34. Schmidt K., Olesen O., Jensen P.: Citalopram and breast-feeding: Serum concentration and side effects in the infant. Biol. Psychiatry 47: 164-165 (2000)

35. Kristensen J., et al.: The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J. Hum. Lact. 18: 139-143 (2002)

36. Eperson N., Jatlow P., Czarkowski K., Anderson G.: Maternal fluoxetine treatment in postpartum period: effects on platelet serotonin and plasma drug levels in breast feeding mother-infant pairs. Pediatrics 112: 425-429 (2003)

37. Weissman A.l., et al.: Pooled analysis of antidepres-sant levels in lactating mothers, breast milk and nursing infants. Am. J. Psychiatry 161: 1066-1078 (2004)

38. Εθνικό συνταγολόγιο, ΕΟΦ, Αθήνα, 2003, σελ. 210.

39. Marcus S.M., Barry K.L., Flynn H.A., Tandon R., Greden J.F.: Treatment guidelines for depression in pregnancy. Int. J. Gynecol. Obstet. 72: 61-70 (2001)